Patriot Financial Group Insurance Agency LLC Purchases 1,011 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Patriot Financial Group Insurance Agency LLC lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,752 shares of the medical research company’s stock after acquiring an additional 1,011 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in IQVIA were worth $1,331,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. Caprock Group LLC raised its stake in shares of IQVIA by 8.9% during the fourth quarter. Caprock Group LLC now owns 1,227 shares of the medical research company’s stock valued at $284,000 after acquiring an additional 100 shares during the last quarter. Global Retirement Partners LLC increased its position in shares of IQVIA by 1.9% during the fourth quarter. Global Retirement Partners LLC now owns 9,609 shares of the medical research company’s stock worth $2,044,000 after buying an additional 176 shares during the period. Clear Harbor Asset Management LLC increased its position in shares of IQVIA by 84.5% during the fourth quarter. Clear Harbor Asset Management LLC now owns 3,322 shares of the medical research company’s stock worth $769,000 after buying an additional 1,521 shares during the period. Meadow Creek Wealth Advisors LLC acquired a new stake in shares of IQVIA during the fourth quarter worth $238,000. Finally, Trueblood Wealth Management LLC acquired a new stake in IQVIA in the fourth quarter worth $261,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.1 %

Shares of IQV traded up $0.32 during trading hours on Friday, reaching $252.89. 771,448 shares of the company traded hands, compared to its average volume of 901,423. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a market capitalization of $45.90 billion, a price-to-earnings ratio of 34.69, a price-to-earnings-growth ratio of 2.44 and a beta of 1.51. The company’s fifty day moving average price is $237.22 and its two-hundred day moving average price is $218.02. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. IQVIA’s revenue was up 3.5% on a year-over-year basis. During the same period last year, the company posted $2.54 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Evercore ISI lifted their price objective on shares of IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 15th. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. BTIG Research began coverage on shares of IQVIA in a research note on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. Finally, Guggenheim cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $256.80.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock valued at $10,331,003. Insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.